Related Experiment Video

Updated: Mar 23, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

Effects of TNFα, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma

C Basmaci1, M Pehlivan, Ag Tomatir

  • 1Department of Hematology, Gaziantep University Faculty of Medicine, Gaziantep,Turkey E-mail : tomatir@pau.edu.tr or aysegaye@hotmail.com.

Asian Pacific Journal of Cancer Prevention : APJCP
|April 5, 2016
PubMed

Insights

Certain gene variations in tumor necrosis factor alpha (TNFα) and nitric oxide synthesis 3 (NOS3) may influence multiple myeloma (MM) development. These genetic factors, specifically TNFα (-308) GG and NOS3 (+894) TT genotypes, were more prevalent in MM patients.

Area of Science:

  • Genetics
  • Oncology
  • Pharmacogenomics

Background:

  • The contribution of gene polymorphisms to drug efficacy in multiple myeloma (MM) remains unclear.
  • Understanding these genetic associations is crucial for personalized treatment strategies in MM.

Purpose of the Study:

  • To investigate the relationship between gene polymorphisms in tumor necrosis factor alpha (TNFα), nitric oxide synthesis 3 (NOS3), and multi-drug resistance 1 (MDR1) with clinical parameters, prognosis, and survival in MM patients.
  • To identify potential genetic markers associated with MM pathogenesis.

Main Methods:

  • Genotyping of TNFα, NOS3, and MDR1 was performed using PCR and/or PCR-RFLP in 77 MM patients and 77 healthy controls.
  • Analysis included various treatment regimens such as VAD, MP, ASCT, BODEC, and TD.

Main Results:

  • No significant differences were observed for TNFα (-238, -857) and MDR1 gene polymorphisms between MM patients and controls.
  • The TNFα (-308) GG genotype (p=0.012) and NOS3 (+894) TT genotype (p=0.008) were more frequent in the MM group.
  • Conversely, NOS3 (VNTR) AA (p=0.007) and NOS3 (+894) GG genotypes (p=0.004) were less common in MM patients.

Conclusions:

  • The NOS3 (+894) TT and TNFα (-308) GG genotypes may play a role in the pathogenesis of multiple myeloma.
  • These findings suggest potential genetic predispositions that could influence MM development.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K